Skip to main content
Premium Trial:

Request an Annual Quote

Denis Burger, Jack Bowman

Premium
Antisense drug firm AVI BioPharma said this week that chairman and CEO Denis Burger has resigned.
 
In a statement, Burger said he is retiring.
 
Jack Bowman, AVI’s independent lead director, has been named chairman, while another independent director, Michael Forrest, has been named interim CEO.
 
"Denis Burger has made a tremendous contribution to the growth and development of AVI,” Bowman said in a statement. "The board has full confidence in AVI's executive team and we look forward to working with Mike Forrest in selecting a new leader to expand the company's footprint, accelerate selection and development of clinical candidates, and improve our market opportunities."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.